Journal article
Treatment with novel oral anticoagulants
Abstract
PURPOSE OF REVIEW: To summarize data relevant to novel oral anticoagulants (nOACs), mainly apixaban, dabigatran and rivaroxaban, as alternatives to vitamin K antagonists (VKAs).
RECENT FINDINGS: RE-LY was the first contemporaneous study to compare a nOAC, dabigatran, with dose-adjusted warfarin, for prevention of stroke and systemic embolism in atrial fibrillation. Since then multiple studies have compared nOACs to warfarin for acute (RE-COVER, …
Authors
Ghanny S; Crowther M
Journal
Current Opinion in Hematology, Vol. 20, No. 5, pp. 430–436
Publisher
Wolters Kluwer
Publication Date
September 2013
DOI
10.1097/moh.0b013e328363c170
ISSN
1065-6251